TC Biopharm (Holdings) Statistics
Total Valuation
TCBP has a market cap or net worth of $361,727. The enterprise value is $1.18 million.
Important Dates
The next estimated earnings date is Sunday, February 9, 2025, before market open.
Earnings Date | Feb 9, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
TCBP has 548,071 shares outstanding.
Current Share Class | n/a |
Shares Outstanding | 548,071 |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +230.71% |
Owned by Insiders (%) | 0.46% |
Owned by Institutions (%) | 1.70% |
Float | 517,784 |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.13 |
P/TBV Ratio | 0.20 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.12, with a Debt / Equity ratio of 0.83.
Current Ratio | 1.12 |
Quick Ratio | 0.64 |
Debt / Equity | 0.83 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -142.89 |
Financial Efficiency
Return on equity (ROE) is -577.04% and return on invested capital (ROIC) is -182.74%.
Return on Equity (ROE) | -577.04% |
Return on Assets (ROA) | -98.20% |
Return on Capital (ROIC) | -182.74% |
Revenue Per Employee | n/a |
Profits Per Employee | -$356,739 |
Employee Count | 41 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | -764,918 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.10% in the last 52 weeks. The beta is 0.02, so TCBP's price volatility has been lower than the market average.
Beta (5Y) | 0.02 |
52-Week Price Change | -97.10% |
50-Day Moving Average | 1.47 |
200-Day Moving Average | 7.74 |
Relative Strength Index (RSI) | 37.47 |
Average Volume (20 Days) | 1,929,979 |
Short Selling Information
Short Interest | 19,061 |
Short Previous Month | 38,332 |
Short % of Shares Out | 3.48% |
Short % of Float | 3.68% |
Short Ratio (days to cover) | 0.05 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -14.99M |
Pretax Income | n/a |
Net Income | -14.63M |
EBITDA | -14.32M |
EBIT | -14.99M |
Earnings Per Share (EPS) | -$78.81 |
Full Income Statement Balance Sheet
The company has $1.27 million in cash and $2.09 million in debt, giving a net cash position of -$820,451 or -$1.50 per share.
Cash & Cash Equivalents | 1.27M |
Total Debt | 2.09M |
Net Cash | -820,451 |
Net Cash Per Share | -$1.50 |
Equity (Book Value) | 2.53M |
Book Value Per Share | 5.12 |
Working Capital | 535,665 |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$11.17 million and capital expenditures $34,950, giving a free cash flow of -$11.07 million.
Operating Cash Flow | -11.17M |
Capital Expenditures | 34,950 |
Free Cash Flow | -11.07M |
FCF Per Share | -$20.20 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
TCBP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -4,043.46% |
FCF Yield | -3,061.07% |
Analyst Forecast
The average price target for TCBP is $3.00, which is 354.55% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $3.00 |
Price Target Difference | 354.55% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on August 5, 2024. It was a reverse split with a ratio of 0.1:1.
Last Split Date | Aug 5, 2024 |
Split Type | Reverse |
Split Ratio | 0.1:1 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |